KA/EN
Register
Medicines reference
Search
Search
Product

Meloxicam Bioveta

Favourites

Meloxicam · Bioveta

2 forms: solution, suspension. In force in Georgia: 2 of 2 (veterinary register).

Forms and doses2 of 2 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
Solution · Cat Cat 0.3 mg/kg
A single injection under the skin before surgery, for example at induction of anaesthesia: 0.3 mg/kg (0.06 ml/kg). This label gives cats no repeat dose and no oral follow-up. Measure the dose accurately. Not under 2 kg or 6 weeks; not into a vein in cats.
 · once, before surgery (single dose)		 once, before surgery (single dose) Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მელოქსიკამი ბიოვეტა 5 მგ/მლ საინექციო ხსნარი ძაღლებისა და კატებისთვის
№ 331-11, 000630
Verified on: 15 Oct 2026
Solution · Dog Dog 0.2 mg/kg
Authorized veterinary meloxicam for dogs and cats. All 3 regimens are single injections: dog, musculoskeletal disorder, 0.2 mg/kg SC; dog, preoperative, 0.2 mg/kg IV or SC; cat, postoperative, 0.3 mg/kg SC only (0.06 mL/kg). The feline label does not permit IV use. Cardiac dysfunction and bleeding disorders are contraindications; a cardiac patient receiving anticoagulant and antiplatelet treatment may have both risks. Do not use in cats below 2 kg or animals below 6 weeks of age.
 · once (SC; before surgery SC or IV)		 once (SC; before surgery SC or IV) Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მელოქსიკამი ბიოვეტა 5 მგ/მლ საინექციო ხსნარი ძაღლებისა და კატებისთვის
№ 331-11, 000630
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Meloxicam Bioveta, Solution

Meloxicam 5 mg/ml, solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full labelled canine injectable scope for peri-operative pain and inflammation and acute musculoskeletal disorders
7.8/10
Good
vetman assessment

Meloxicam Bioveta

Meloxicam 5 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeDog · Full labelled canine injectable scope for peri-operative pain and inflammation and acute musculoskeletal disorders · SC,IV
Care settingVeterinary-administered peri-operative or acute NSAID analgesia after hydration, renal, gastrointestinal and anaesthetic risk assessment
vetman score 7.8/10 Good
Evidence confidence: High Georgia: Yes, veterinary · № 331-11, 000630 · Verified on 15 Oct 2026

An effective established injectable canine NSAID for peri-operative and acute musculoskeletal pain when hydration, renal/GI risk and concurrent analgesics are actively managed.

Regulatory and scientific credibility8.5/10

The exact Bioveta formulation is registered in Georgia and has current official EU product information; meloxicam also has mature international regulatory review and long clinical use.

Clinical efficacy8.5/10

Randomized and comparative studies support clinically meaningful analgesic and anti-inflammatory efficacy in canine osteoarthritis and musculoskeletal pain, with extensive class-level experience.

Safety and tolerability6.5/10

The safety profile is well characterised but not benign: gastrointestinal ulceration or bleeding, renal injury and hepatic reactions can be serious, especially with dehydration, comorbidity, overdose or NSAID/corticosteroid overlap.

Clinical practicality7.5/10

Injection is useful when oral dosing is unsuitable and allows controlled peri-operative use, but requires veterinary administration and careful timing around anaesthesia and fluid status.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not combine with another NSAID or corticosteroid and do not switch without an appropriate veterinarian-determined washout period.
  • Avoid in dehydrated, hypovolaemic or hypotensive animals and in patients with gastrointestinal ulceration or significant renal, hepatic, cardiac or coagulation disease unless a specialist benefit-risk decision supports use.
  • Stop treatment and reassess promptly for vomiting, diarrhoea, melaena, anorexia, lethargy, altered drinking/urination, jaundice or other suspected NSAID toxicity.
  • Use the lowest effective dose for the shortest necessary duration and obtain baseline/interval renal, hepatic and haematologic assessment according to patient risk and course length.
  • For cats, this assessment covers only the labelled single injection: do not administer an additional injectable or oral meloxicam dose unless a separate locally authorised feline regimen explicitly permits it.
Assessment sources
  1. Meloxicam Bioveta, EMA UPD 20262026
  2. FDA Metacam label2023
  3. Meloxicam canine OA placebo trial2000
  4. Meloxicam canine OA comparative trial2003
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full labelled feline injectable scope for postoperative pain after ovariohysterectomy and minor soft-tissue surgery
7.2/10
Good
vetman assessment

Meloxicam Bioveta

Meloxicam 5 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeCat · Full labelled feline injectable scope for postoperative pain after ovariohysterectomy and minor soft-tissue surgery · Subcutaneous
Care settingSingle-dose veterinarian-administered peri-operative NSAID analgesia in a well-hydrated, screened cat as part of multimodal pain control
vetman score 7.2/10 Good
Evidence confidence: High Georgia: Yes, veterinary · № 331-11, 000630 · Verified on 15 Oct 2026

An evidence-based single-dose feline peri-operative NSAID option, but the narrow safety margin and repeat-dose hazard make strict screening, hydration and multimodal planning non-negotiable.

Regulatory and scientific credibility8.5/10

The exact 5 mg/ml Bioveta injection is registered in Georgia with current official EU product information, and injectable meloxicam has mature international regulatory review in cats.

Clinical efficacy7.5/10

Randomized peri-operative trials support single-dose analgesic activity, but efficacy varies by procedure and comparator and meloxicam should remain one component of multimodal analgesia rather than sole rescue coverage.

Safety and tolerability5.5/10

Cats have a narrow NSAID safety margin; renal injury and gastrointestinal toxicity are major concerns with hypovolaemia, hypotension, renal disease, overdose or repeat dosing. The assessed role is strictly the labelled single injection.

Clinical practicality7.5/10

A single veterinary injection is straightforward within an anaesthetic protocol, but timing, hydration and the absolute prohibition on unplanned repeat dosing require disciplined workflow.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not combine with another NSAID or corticosteroid and do not switch without an appropriate veterinarian-determined washout period.
  • Avoid in dehydrated, hypovolaemic or hypotensive animals and in patients with gastrointestinal ulceration or significant renal, hepatic, cardiac or coagulation disease unless a specialist benefit-risk decision supports use.
  • Stop treatment and reassess promptly for vomiting, diarrhoea, melaena, anorexia, lethargy, altered drinking/urination, jaundice or other suspected NSAID toxicity.
  • Use the lowest effective dose for the shortest necessary duration and obtain baseline/interval renal, hepatic and haematologic assessment according to patient risk and course length.
  • For cats, this assessment covers only the labelled single injection: do not administer an additional injectable or oral meloxicam dose unless a separate locally authorised feline regimen explicitly permits it.
Assessment sources
  1. Meloxicam Bioveta, EMA UPD 20262026
  2. FDA Metacam label2023
  3. Meloxicam feline perioperative RCT2012
  4. Meloxicam feline OHE RCT2002
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Meloxicam5 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous, Intravenous
Manufacturer
Bioveta · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მელოქსიკამი ბიოვეტა 5 მგ/მლ საინექციო ხსნარი ძაღლებისა და კატებისთვის
№ 331-11, 000630
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-219
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
0.3 mg/kg
A single injection under the skin before surgery, for example at induction of anaesthesia: 0.3 mg/kg (0.06 ml/kg). This label gives cats no repeat dose and no oral follow-up. Measure the dose accurately. Not under 2 kg or 6 weeks; not into a vein in cats.
 Cat Any weight Subcutaneous once, before surgery (single dose)
Meloxicam Bioveta, EMA UPD 2026
Official product label (SPC), UPD, EU
Approved by an EU medicines regulator (published in the EU Union Product Database, UPD) as part of the product's authorisation. It applies to that product as authorised there.
Meloxicam Bioveta 5 mg/ml solution for injection - Summary of Product Characteristics (Czech)
EU Union Product Database, 2026
0.2 mg/kg
Authorized veterinary meloxicam for dogs and cats. All 3 regimens are single injections: dog, musculoskeletal disorder, 0.2 mg/kg SC; dog, preoperative, 0.2 mg/kg IV or SC; cat, postoperative, 0.3 mg/kg SC only (0.06 mL/kg). The feline label does not permit IV use. Cardiac dysfunction and bleeding disorders are contraindications; a cardiac patient receiving anticoagulant and antiplatelet treatment may have both risks. Do not use in cats below 2 kg or animals below 6 weeks of age.
 Dog Any weight Subcutaneous once (SC; before surgery SC or IV)
Meloxicam Bioveta, EMA UPD 2026
Official product label (SPC), UPD, EU
Approved by an EU medicines regulator (published in the EU Union Product Database, UPD) as part of the product's authorisation. It applies to that product as authorised there.
Meloxicam Bioveta 5 mg/ml solution for injection - Summary of Product Characteristics (Czech)
EU Union Product Database, 2026
1.5 mg/ml, Suspension · Dog Dog Loading · By mouth: 0.2 mg/kgMaintenance · By mouth: 0.1 mg/kg - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მელოქსიკამი ბიოვეტა 1.5 მგ/მლ პერორალური სუსპენზია ძაღლებისთვის
Verified on: 18 Oct 2026
Details: pack, label wording, sources, registration

Meloxicam Bioveta 1.5 mg/ml, Suspension

meloxicam 1.5 mg/ml, oral suspension for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.9/10
Good
vetman assessment

Meloxicam Bioveta

1.5 mg/ml, meloxicam 1.5 mg/ml, oral suspension for dogs
Assessed clinical scopeDog · Full labelled canine oral scope for alleviation of inflammation and pain in acute and chronic musculoskeletal disorders · By mouth
Care settingVeterinary-prescribed daily NSAID therapy with baseline risk assessment and ongoing response/toxicity monitoring
vetman score 7.9/10 Good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 18 Oct 2026

A well-supported canine NSAID option with practical once-daily dosing, provided patient selection, lowest-effective-dose use and gastrointestinal/renal/hepatic monitoring are rigorous.

Regulatory and scientific credibility8.5/10

The exact Bioveta formulation is registered in Georgia and has current official EU product information; meloxicam also has mature international regulatory review and long clinical use.

Clinical efficacy8.5/10

Randomized and comparative studies support clinically meaningful analgesic and anti-inflammatory efficacy in canine osteoarthritis and musculoskeletal pain, with extensive class-level experience.

Safety and tolerability6.5/10

The safety profile is well characterised but not benign: gastrointestinal ulceration or bleeding, renal injury and hepatic reactions can be serious, especially with dehydration, comorbidity, overdose or NSAID/corticosteroid overlap.

Clinical practicality8.0/10

Once-daily oral suspension supports precise weight-based dosing and course adjustment, but the bottle must be shaken, the syringe used accurately and daily clinical monitoring maintained.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not combine with another NSAID or corticosteroid and do not switch without an appropriate veterinarian-determined washout period.
  • Avoid in dehydrated, hypovolaemic or hypotensive animals and in patients with gastrointestinal ulceration or significant renal, hepatic, cardiac or coagulation disease unless a specialist benefit-risk decision supports use.
  • Stop treatment and reassess promptly for vomiting, diarrhoea, melaena, anorexia, lethargy, altered drinking/urination, jaundice or other suspected NSAID toxicity.
  • Use the lowest effective dose for the shortest necessary duration and obtain baseline/interval renal, hepatic and haematologic assessment according to patient risk and course length.
  • For cats, this assessment covers only the labelled single injection: do not administer an additional injectable or oral meloxicam dose unless a separate locally authorised feline regimen explicitly permits it.
Assessment sources
  1. UPD SPC 20262026
  2. FDA Metacam label2023
  3. Meloxicam canine OA placebo trial2000
  4. Meloxicam canine OA comparative trial2003
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Meloxicam1.5 mg/ml
Formulation Type
Suspension
Administration route
By mouth
Manufacturer
Bioveta · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: მელოქსიკამი ბიოვეტა 1.5 მგ/მლ პერორალური სუსპენზია ძაღლებისთვის
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ 96/022/19-C
Verified on: 18 Oct 2026
 UK No
Verified on: 18 Oct 2026
 US No
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Dog
WeightLoading · By mouthMaintenance · By mouth
Any weight 0.2 mg/kg 0.1 mg/kg
  • Loading · By mouth (once, day 1): Day 1: 0.2 mg/kg (1 ml per 7.5 kg) with food or into the mouth. Shake well.
  • Maintenance · By mouth (once daily): From day 2: 0.1 mg/kg (1 ml per 15 kg) once a day. Not for cats.
Source:
UPD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
MELOXICAM Bioveta 1.5 mg/ml oral suspension for dogs - SPC (Czech Republic)
EU Union Product Database, 2026
Active substance doses, with sources
Active substance Meloxicam
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.1 mg/kg Dog Maintenance By mouth once daily
Source: EMA UPD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
MELOXICAM Bioveta 1.5 mg/ml oral suspension for dogs - SPC (Czech Republic)
EU Union Product Database, 2026
0.2 mg/kg Dog Inflammation Subcutaneous once
Norbrook Meloxicam, VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
0.2 mg/kg Dog Loading By mouth once, day 1
Source: EMA UPD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
MELOXICAM Bioveta 1.5 mg/ml oral suspension for dogs - SPC (Czech Republic)
EU Union Product Database, 2026
0.2 mg/kg Dog Inflammation
Premedication
 Intravenous once
Norbrook Meloxicam, VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
0.3 mg/kg Cat Inflammation Subcutaneous once
Norbrook Meloxicam, VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024

Known Contraindications

  • Critical
    Do not use in animals suffering from... impaired hepatic, cardiac or renal function
    Sources: VMD SPC · VMD
  • Critical
    Do not use meloxicam in animals with impaired cardiac function.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals suffering from... haemorrhagic disorders.
    Sources: VMD SPC · VMD
  • Critical
    Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
    Sources: VMD SPC · VMD
  • Critical
    Hepatic impairment is a contraindication.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage
    Sources: VMD SPC · VMD
  • Critical
    Do not use meloxicam during pregnancy.
    Sources: VMD SPC · VMD
  • Critical
    Do not use meloxicam during lactation.
    Sources: VMD SPC · VMD
  • Critical
    Known hypersensitivity to meloxicam or any excipient is a contraindication.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals less than 6 weeks of age
    Sources: VMD SPC · VMD
  • Critical (Cat)
    USA (FDA label, Metacam injection): cats get one injection only, 0.3 mg/kg under the skin. The boxed warning links repeated meloxicam in cats with acute kidney failure and death; give no further meloxicam or other NSAID after it. The US oral suspension is labelled for dogs only.
    Sources: FDA
  • Warning
    Avoid use in any dehydrated, hypovolaemic or hypotensive animal
    Sources: VMD SPC · VMD
  • Warning (Cat)
    Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.
    Sources: VMD SPC · VMD
  • Warning (Cat)
    Cats (EU label, Metacam): the injection is one dose before surgery. Oral meloxicam after surgery (0.05 mg/kg once daily) may follow for at most 4 days, 5 days in all. For acute musculoskeletal pain the oral dose continues only while the acute pain lasts; for chronic disease it is a long-term 0.05 mg/kg daily dose with regular review, stopped after 14 days if there is no improvement. Do not give cats a dog formulation.
    Source: EMA Sources: EMA · EU UPD

Known Drug Interactions

  • Contraindicated Meloxicam + Prednisolone
    Concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs can worsen gastrointestinal ulceration.
    Recommendation: Do not administer together. Observe an appropriate washout period when switching and monitor for melena, vomiting, and reduced appetite.
    Sources: Product label
  • Contraindicated Meloxicam + Robenacoxib
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Meloxicam + Carprofen
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA
  • Major warning Meloxicam + Dexamethasone
    The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration.
    Recommendation: Avoid concurrent administration. Observe an appropriate washout period when switching. If both are essential, provide gastroprotection and monitor gastrointestinal signs closely.
    Sources: VMD SPC · VMD
  • Major warning Amikacin + Meloxicam
    Concurrent amikacin and Meloxicam can increase nephrotoxic and/or ototoxic risk.
    Recommendation: Avoid the combination when a safer effective alternative exists. If unavoidable, correct hydration and intensify renal, urine and clinical monitoring.
    Sources: ISCAID · MSD Vet Manual

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (4 more) Hide additional products

Same therapeutic group 4

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗